Taiwan - Delayed Quote TWD

Pell Bio-Med Technology Co., Ltd. (6949.TW)

Compare
80.00
0.00
(0.00%)
At close: 1:20:39 PM GMT+8

Key Executives

Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in TWD.
NameTitlePayExercisedYear Born
Mr. Cheng Long Lin GM & Chairman -- -- --
Chang-Min Wu Financial Officer, Accounting Officer & Corporate Governance Officer -- -- --

Pell Bio-Med Technology Co., Ltd.

No. 87, Xinhu 2nd Rd.
4th Floor Neihu Dist.
Taipei
Taiwan
886 2 8791 1789 https://www.pellbmt.com
Sector: 
Healthcare
Industry: 
Biotechnology

Description

Pell Bio-Med Technology Co., Ltd., a biomedical company, engages in the development of cell culture technologies and techniques for therapeutic applications. Its commercial products include good tissue practice laboratory infrastructure, adipose-derived stem cells (ADSC) for regenerative medicine, and CIK and DC-CIK against cancers. The company also develops medicines for various types of cancers, cell immunotherapy, and stem cell regenerative therapy technologies. In addition, it engages in the research and development of chimeric antigen receptor T cell (CAR-T), CAR-NK and CAR-?dT, and gene-modified ADSC. Further, the company develops products for B-NHL, ovarian cancer, multiple myeloma, and thyroid cancer indications. The company was founded in 2017 and is based in Taipei, Taiwan.

Corporate Governance

Pell Bio-Med Technology Co., Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

Related Tickers